This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
CESPHN is seeking expressions of interest from General Practitioners and Practice Nurses who would like to be involved as members of an immunisation working group. This will involve attending two video conference meetings per year with CESPHN and the Public Health Unit, and participate in discussions around immunisation planning and review of strategies. Representatives will be paid for their attendance as per the rate in the CESPHN Representation Policy.
Closure of schools in Terms 3 and 4 has interrupted NSW Health’s routine school-based vaccination program, resulting in adolescents needing access to routine vaccinations via their GP in the interim. Adolescents may present to general practice for routine HPV, dTpa or MenACWY vaccination. Providers are encouraged to offer a free HPV, dTpa or MenACWY vaccine to eligible students upon request. See the full NSW Health statement. More general advice for parents and schools is available on the NSW Health website.
When entering directly onto the AIR site, there is no requirement for entering a dose number for adults. AIR record all adult doses as V (valid). The immunisation history statement does not list doses for adults.
For children it does require you to enter dose number. There are no boosters yet for children, but further information will be provided as advice changes.
If you are required to enter a dose number, it can be entered as ‘3’ but AIR will count them according to date given so it does not need to be changed if it automatically defaults to ‘1’ in practice software.
The mandatory training modules for COVID-19 vaccination providers have now been updated with new information on COVID-19 booster shots. Log in to the COVID-19 Vaccination Training Program to view updates.
COVID-19 vaccines given overseas since 1 October 2020 that have been recognised by the Therapeutic Goods Administration (TGA) can now be recorded on the Australian Immunisation Register (AIR).
AstraZeneca COVISHIELD
AstraZeneca Vaxzevria
Bharat (Covaxin)
Janssen-Cilag COVID Vaccine
Moderna Spikevax
Pfizer/Biontech Comirnaty
Sinopharm BBIBP-CorV
Sinovac Coronavac
It is important that country of immunisation and batch number are recorded. A list of all vaccines currently able to be reported to AIR is available on the AIR vaccine code page which is updated regularly.
Smart Traveller also has advice for international travel and COVID-19 vaccination.
While it is preferable to use the same brand for both doses of the primary course, an alternative brand can be used for the second dose in select circumstances including if a patient is unable to access or not accepting of a second dose of the same brand. There is emerging data supporting the safety and efficacy of mixed brand schedules. See ATAGI clinical advice on use of a different COVID-19 vaccine as the second dose in special circumstances
Updated drug dose thresholds: people taking ≥10mg/week of methotrexate, ≥1mg/kg/day of azathioprine or ≥0.5mg/kg/day of 6-mercaptopurine are recommended to have a 3rd primary dose of a COVID-19 vaccine
Clarification that people with functional or anatomical asplenia do not require a 3rd primary dose
A table of examples of biologic agents has been added
People with severe immunocompromise have been recommended to receive a third dose as part of their primary COVID-19 vaccination course, and at this stage are not recommended to receive any further (i.e., 4th) doses. See COVID-19 vaccination decision guide for people with immunocompromise
At this stage no additional doses (including booster doses) are recommended for people with severe immunocompromise who have received 3 doses of a COVID-19 vaccine. Further (i.e., 4th) doses are not recommended at this time. See Provider guide to COVID-19 vaccination of people with immunocompromise
Updated information on the rate of myocarditis or pericarditis temporally associated with mRNA vaccines
Updated guidance on the precautions for people with a past history of pericarditis or myocarditis; ‘recent’ myocarditis or pericarditis is defined as within the last 3 months (previously 6 months).
Updated guidance on assessment and referral of suspected myocarditis or pericarditis in primary care and emergency departments.
Updated guidance on revaccination after suspected myocarditis or pericarditis.
Figure 2: Approach to revaccination in people with pericarditis attributed to an mRNA COVID-19 vaccine
The Australian Technical Advisory Group on Immunisation (ATAGI) 2021 Annual Statement on Immunisation has been published in the Communicable Diseases Intelligence journal. It is the first publication in what will be a regular series.
The statement highlights the key successes, trends and challenges in the use of vaccines and control of vaccine preventable diseases (VPDs) in Australia in 2020. The statement also signals ATAGI’s priority actions for addressing key issues for 2021 and beyond.
Join the latest COVID-19 vaccine live stream update for GPs. The panel will provide latest key updates and answer participants’ questions live about the COVID-19 vaccine rollout. Get involved by submitting questions and comments!
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Launch of new Australian Guideline for assessing and managing cardiovascular disease risk The 2023 Australian Guideline for assessing and managing cardiovascular disease risk, and associated Australian cardiovascular disease risk calculator (Aus CVD Risk Calculator), will become the new standard of care for the primary prevention of CVD in Australia. This…
At CESPHN we value your feedback and invite you to complete the 2023 stakeholder engagement survey At CESPHN, we value your feedback and invite you to complete the stakeholder engagement survey on our service delivery and communication over the past 12 months. This short survey only takes five minutes and…
CESPHN Healthy Ageing Strategy 2023-28 has been released The Central and Eastern Sydney PHN has developed a Healthy Ageing Strategy to empower older people in our region to live more active and fulfilling lives, enabled by inclusive communities, and supported by integrated person-centred health and social services. Healthy ageing relies…
NSW community urged to be on alert amid rise in listeriosis NSW Health is reminding people who are immunocompromised, pregnant, or aged over 65 years to avoid foods that can cause listeriosis, following several confirmed cases of listeria infection in NSW. Listeriosis infection, which comes from consuming food contaminated with…
CESPHN Primary Health Awards: 2023 Finalists and Winners announced At a packed event last night at the Hazelhurst Arts Centre in Gymea, CESPHN held its annual Primary Health Awards. CESPHN’s multicultural community was reflected in our numerous and diverse submissions. All immensely impressive. The winners, announced at the awards event,…